Bevacizumab Treatment and Retinal Vessel Monitoring
NCT00740168 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2016-01-21
Summary
Bevacizumab might influence the dynamic vessel function after being administered intravenously.
Conditions
Interventions
- DRUG
-
bevacizumab treatment
single infusion 10 mg/kg
Sponsors & Collaborators
-
Technische Universität Dresden
lead OTHER
Principal Investigators
-
Tjalf Ziemssen, MD · Neurological University Clinic
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-05-31
- Primary Completion
- 2008-12-31
- Completion
- 2009-04-30
Countries
- Germany
Study Locations
More Related Trials
-
Bevacizumab Effect on Blood Velocity
NCT01298440 ·Status: COMPLETED
-
Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
NCT04138420 ·Status: COMPLETED
-
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00556348 ·Status: COMPLETED ·Phase: PHASE4
-
Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
NCT00423059 ·Status: COMPLETED ·Phase: NA
-
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
NCT00898794 ·Status: UNKNOWN
-
Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease
NCT01041690 ·Status: COMPLETED ·Phase: NA
-
The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)
NCT00640640 ·Status: UNKNOWN ·Phase: NA
-
Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
NCT03744806 ·Status: COMPLETED
-
Visual Outcome After Vitrectomy With Subretinal tPA Injection
NCT05196139 ·Status: COMPLETED
-
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
NCT01327222 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Retreatments With Intravitreal Bevacizumab
NCT00406744 ·Status: TERMINATED ·Phase: PHASE3
-
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
NCT00797992 ·Status: COMPLETED ·Phase: PHASE4
-
Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
NCT01025934 ·Status: COMPLETED ·Phase: PHASE4
-
Retinal Vessel Diameter in Branch Retinal Vein Occlusion
NCT02215109 ·Status: COMPLETED
-
VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
NCT00727753 ·Status: COMPLETED
-
Systemic Avastin Therapy in Age-Related Macular Degeneration
NCT00531024 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)
NCT00370721 ·Status: UNKNOWN ·Phase: PHASE3
-
Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial
NCT00370851 ·Status: COMPLETED ·Phase: PHASE3
-
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
NCT00599820 ·Status: TERMINATED ·Phase: PHASE3
-
The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
NCT00709657 ·Status: TERMINATED ·Phase: NA
-
Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea
NCT01501760 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
NCT00370370 ·Status: UNKNOWN ·Phase: PHASE3
-
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
NCT00729846 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab and Retinal Vascular Occlusions
NCT00347711 ·Status: WITHDRAWN ·Phase: PHASE3
-
Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
NCT00407719 ·Status: COMPLETED ·Phase: PHASE1